New Blood Test Predicts Kidney Failure Years Before Symptoms Appear

A groundbreaking blood test can identify individuals of African ancestry who are at the highest risk of developing kidney failure long before clinical symptoms emerge. The test focuses on people carrying high-risk variants of the APOL1 gene and was developed by researchers at the Perelman School of Medicine at the University of Pennsylvania. The findings were published in Nature Medicine.

Until now, clinicians lacked reliable tools to detect early disease activity before standard indicators of kidney damage became visible. This new approach enables earlier intervention, potentially reducing disease severity or even preventing kidney failure in some patients.

Kidney failure occurs nearly four times more often in African Americans compared to individuals of European descent, partly due to APOL1 gene variants. While these variants can protect against certain infections, they also increase the risk of serious kidney disease. Although millions of people carry these variants, most do not develop the condition, and identifying those at real risk has remained a challenge.

The researchers analyzed blood samples from more than 850 individuals of African ancestry who carried high-risk APOL1 variants but initially had normal kidney function. By measuring a small group of proteins in the blood, they developed a predictive score that estimates the risk of kidney failure, major decline in kidney function, or death over the next decade.

The results showed a striking contrast: over 60% of individuals in the highest-risk group developed kidney failure requiring dialysis or transplantation within ten years, compared to less than 1% in the lowest-risk group.

The proteins used in the test are linked to biological pathways involved in kidney damage and fibrosis, indicating that the method detects early changes before traditional clinical signs appear.

The findings were confirmed in independent cohorts in both the United States and the United Kingdom, where the new model consistently outperformed existing prediction tools.

Researchers believe the test could become part of routine clinical practice, helping guide monitoring and treatment decisions—especially as new therapies targeting APOL1-related kidney disease are being developed. These include experimental drugs aimed at blocking the harmful effects of high-risk gene variants.

The team is now working to bring the test into clinical use and explore how it can support patient care and future clinical trials.